These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38847597)

  • 1. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC).
    Matsumoto M; Polli JR; Swaminathan SK; Datta K; Kampershroer C; Fortin MC; Salian-Mehta S; Dave R; Yang Z; Arora P; Hiura M; Suzuki M; Brennan FR; Sathish J
    Clin Pharmacol Ther; 2024 Sep; 116(3):546-562. PubMed ID: 38847597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
    Leach MW; Clarke DO; Dudal S; Han C; Li C; Yang Z; Brennan FR; Bailey WJ; Chen Y; Deslandes A; Loberg LI; Mayawala K; Rogge MC; Todd M; Chemuturi NV
    Clin Pharmacol Ther; 2021 Jun; 109(6):1395-1415. PubMed ID: 32757299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.
    Ji Y; Knee D; Chen X; Dang A; Mataraza J; Wolf B; Sy SKB
    Clin Transl Sci; 2022 Sep; 15(9):2218-2229. PubMed ID: 35731955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.
    Piccotti JR; Lebrec HN; Evans E; Herzyk DJ; Hastings KL; Burns-Naas LA; Gourley IS; Wierda D; Kawabata TT
    J Immunotoxicol; 2009 Mar; 6(1):1-10. PubMed ID: 19519157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology.
    Saber H; Thompson MD; Leighton JK
    Regul Toxicol Pharmacol; 2024 May; 149():105616. PubMed ID: 38561147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
    Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A public-private consortium advances cardiac safety evaluation: achievements of the HESI Cardiac Safety Technical Committee.
    Pierson JB; Berridge BR; Brooks MB; Dreher K; Koerner J; Schultze AE; Sarazan RD; Valentin JP; Vargas HM; Pettit SD
    J Pharmacol Toxicol Methods; 2013; 68(1):7-12. PubMed ID: 23567075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An FDA oncology analysis of immune activating products and first-in-human dose selection.
    Saber H; Gudi R; Manning M; Wearne E; Leighton JK
    Regul Toxicol Pharmacol; 2016 Nov; 81():448-456. PubMed ID: 27743776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
    Suh HY; Peck CC; Yu KS; Lee H
    Drug Des Devel Ther; 2016; 10():4005-4016. PubMed ID: 27994442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human dose: current status review for better future perspectives.
    Mishra A; Sarangi SC; Reeta K
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1237-1243. PubMed ID: 32488334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
    Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
    Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative science in action: A 20 year perspective from the Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee.
    Pierson JB; Berridge B; Blinova K; Brooks MB; Eldridge S; O'Brien CE; Pugsley MK; Schultze AE; Smith G; Stockbridge N; Valentin JP; Vicente J
    J Pharmacol Toxicol Methods; 2024; 127():107511. PubMed ID: 38710237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
    Mayawala K; Tse A; Rubin EH; Jain L; de Alwis DP
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S143-S145. PubMed ID: 28921649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.